<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01445223</url>
  </required_header>
  <id_info>
    <org_study_id>Northiv protocol 3.66</org_study_id>
    <nct_id>NCT01445223</nct_id>
  </id_info>
  <brief_title>A Study on Antiretroviral Therapy (ART) Naïve Patients On Different Regimens to Treat Hiv (NORTHIV)</brief_title>
  <official_title>A Study on ART Naïve Patients On Different Regimens to Treat Hiv (a Phase 4 Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Göteborg University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Göteborg University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study aims to compare efficacy, side-effects, and treatment adherence of three
      different treatment regimens given to antiretroviral naïve HIV-1 infected patients. Treatment
      will be initiated in accordance with the Swedish National Guidelines. In the twice daily
      (BID) arm (1), which could be considered as a standard regimen at present,
      lopinavir/ritonavir, is co-administrated with 2 nucleoside reverse transcriptase inhibitors
      (NRTIs) administrated BID. The first once daily (QD) arm (2) combines the protease inhibitor
      (PI) atazanavir/ritonavir with 2 NRTIs administrated QD, and in the second QD arm (3), the
      non nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz is combined with 2 NRTIs
      administrated QD. All drugs used in the study are licensed in the participating countries and
      patients will be followed as in clinical practice. Patients could optionally, after informed
      consent, be followed with additional measurements of HIV-1 RNA after 1, 2, and 3 weeks of
      treatment to asses the kinetics of viral decline after initiation of treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2004</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intention to treat (ITT)/time to loss of virological response (TLOVR)</measure>
    <time_frame>144 weeks</time_frame>
    <description>Virological failure (see 5.5.2 for definition)
Treatment interruption or change of study treatment due to side-effects
Treatment interruption or change of study treatment due to any other reason
Missed to follow-up
1. HIV-1 RNA &gt;50 copies/ml in two consecutive measurements from week 24 and on 2. any rise in HIV-1 RNA &gt;50 copies/ml in two consecutive measurements after viral load &lt;50 copies/ml has been reached 3. HIV-1 RNA never &lt;50 copies/ml after week 24</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of abnormal laboratory parameters</measure>
    <time_frame>144 weeks</time_frame>
    <description>Incidence of abnormal laboratory parameters at follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence to study medication</measure>
    <time_frame>144 weeks</time_frame>
    <description>Proportion of doses taken correctly</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of adverse events</measure>
    <time_frame>144 weeks</time_frame>
    <description>Proportion of treatment discontinuations and changes due to different adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in CD4 cell counts</measure>
    <time_frame>144 weeks</time_frame>
    <description>Changes in CD4+ T-cell count from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in plasma lipids</measure>
    <time_frame>144 weeks</time_frame>
    <description>Changes from baseline in plasma lipids</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of hyperlipidemia</measure>
    <time_frame>144 weeks</time_frame>
    <description>Incidence of hypercholesterolemia and hypertriglyceridemia at baseline and follow-up</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">242</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>lopinavir/ritonavir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>400/100 mg BID + 2 NRTIs BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>atazanavir/ritonavir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>300mg+100mg QD+ 2 NRTI QD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>efavirenz</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>600mg QD + 2NRTI QD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lopinavir ritonavir</intervention_name>
    <description>400mg BD 100mg BD</description>
    <arm_group_label>lopinavir/ritonavir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atazanavir ritonavir</intervention_name>
    <description>300mg QD 100mg QD</description>
    <arm_group_label>atazanavir/ritonavir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Efavirenz</intervention_name>
    <description>600mg QD</description>
    <arm_group_label>efavirenz</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, aged 16 years of age

          -  HIV-1 infected as documented by a licensed HIV-1 antibody ELISA

          -  Ability to understand and provide informed consent

          -  Indication for antiretroviral treatment

          -  Antiretroviral naïve

          -  All clinical laboratory values not clinically significant

        Exclusion Criteria:

          -  Subjects being pregnant

          -  Women of childbearing potential not practicing birth control

          -  Subjects with renal failure requiring dialysis

          -  Drug interactions with any of the study drugs that are not manageable

          -  Resistance to any of the study drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Magnus Gisslén, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Goteborg Universitet</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Infectious Diseases</name>
      <address>
        <city>Goteborg</city>
        <zip>S-41685</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <link>
    <url>http://www.sahlgrenska.gu.se/</url>
    <description>Goteborg University</description>
  </link>
  <results_reference>
    <citation>Edén A, Andersson LM, Andersson O, Flamholc L, Josephson F, Nilsson S, Ormaasen V, Svedhem V, Säll C, Sönnerborg A, Tunbäck P, Gisslén M. Differential effects of efavirenz, lopinavir/r, and atazanavir/r on the initial viral decay rate in treatment naïve HIV-1-infected patients. AIDS Res Hum Retroviruses. 2010 May;26(5):533-40. doi: 10.1089/aid.2009.0177.</citation>
    <PMID>20455766</PMID>
  </results_reference>
  <results_reference>
    <citation>Josephson F, Andersson MC, Flamholc L, Gisslén M, Hagberg L, Ormaasen V, Sönnerborg A, Vesterbacka J, Böttiger Y. The relation between treatment outcome and efavirenz, atazanavir or lopinavir exposure in the NORTHIV trial of treatment-naïve HIV-1 infected patients. Eur J Clin Pharmacol. 2010 Apr;66(4):349-57. doi: 10.1007/s00228-009-0763-z. Epub 2009 Dec 5.</citation>
    <PMID>19967342</PMID>
  </results_reference>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 28, 2011</study_first_submitted>
  <study_first_submitted_qc>September 30, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 3, 2011</study_first_posted>
  <last_update_submitted>October 2, 2011</last_update_submitted>
  <last_update_submitted_qc>October 2, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 4, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Göteborg University</investigator_affiliation>
    <investigator_full_name>Lars-Magnus Andersson</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Antiretroviral therapy</keyword>
  <keyword>efavirenz</keyword>
  <keyword>lopinavir</keyword>
  <keyword>atazanavir</keyword>
  <keyword>randomised controlled clinical trial</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
    <mesh_term>Atazanavir Sulfate</mesh_term>
    <mesh_term>Efavirenz</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

